Please disable your adblock and script blockers to view this page

Reasons for hope: the drugs, tests and tactics that may conquer coronavirus


GILEAD
WHO
COVID-19
Repurposed Experimental
Gilead
FDA
New England Journal of Medicine
Trump for COVID-19
Journal of Zhejiang Univ (Med Sci
Médecine et Maladies Infectieuses
ACTEMRA
TOCILIZUMAB
KEVZARA
SARILUMAB
REGENERON PHARMACEUTICALS
Regeneron
Sanofi
JAKAVI (RUXOLITINIB
INCYTE Developed
Novartis
KALETRA
LOPINAVIR
Jinyintan Hospital
Kaletra
Mylan
APN01 - APEIRON BIOLOGICS
rhACE2
PAH
The University of Tokyo
ANCA
CLOPIDOGREL
RIVAROXABAN
ATORVASTATIN
J&J
Moderna
NVX
BCG
CHILDREN’S RESEARCH INSTITUTE
UMC UTRECHT
the Max Planck Institute
INO-4800
CEPI
OXFORD Non-
SIDEMU BIOTECHNOLOGY TECHNOLOGY
NK
AstraZeneca
GSK
Abbott
The Lancet Infectious Diseases
Reuters
All Rights Reserved


NEJM
Phase-2
ALI
Pyoderma Gangraenosum
NOVAVAX Novavax
LENTIVIRAL MINIGENE
VPM1002
Preprint
Christine Soares
Nancy LapidAll


Chinese
French
COVID-19


Europe
Key China

No matching tags


China
the United States
France
Canada
Mexico
Incyte
Jakavi
Wuhan
U.S.
Austria
DENMARK
Japan
South Korea
Denmark
Netherlands
the United Kingdom
Shenzen
Australia
Germany
TB
Hubei
CHONGQING
Italy
Britain
UK

No matching tags

Positivity     36.00%   
   Negativity   64.00%
The New York Times
SOURCE: http://feeds.reuters.com/~r/reuters/topNews/~3/dmcQkiPo9Zg/reasons-for-hope-the-drugs-tests-and-tactics-that-may-conquer-coronavirus-idUSKBN21Z2HP
Write a review: Reuters
Summary

STATUS: Repurposed Experimental EARLY RESULTS: 0-3 months Report says COVID-19 patients respond to Gilead’s remdesivir, shares surge Link: here Gilead starts two late-stage studies to test drug for coronavirus Link: here Investors await data on coronavirus drugs as market rally builds Link: here Gilead asks FDA to revoke orphan drug status for potential coronavirus drug Link: here Two thirds of COVID-19 patients improve after Gilead drug: NEJM Link: here Clinical Trials Link: here New England Journal of Medicine, April 2020 Link: here Malaria drug also believed to have antiviral activity. STATUS: Repurposed EARLY RESULTS: 0-3 months Special Report: Doctors embrace drug touted by Trump for COVID-19, without hard evidence it works Link: here Coronavirus drug hopefuls are cheap to make but may be in short supply Link: here Clinical Trials Link: here Journal of Zhejiang Univ (Med Sci), March 2020 Link: here Médecine et Maladies Infectieuses, March 2020 Link: here Nature, February 2020 Link: here ACTEMRA (TOCILIZUMAB) - ROCHE Monoclonal antibody approved for rheumatoid arthritis and also for treating the “cytokine storm” immune overresponse in cancer patients. STATUS: Repurposed EARLY RESULTS: 0-3 months Coronavirus drug hopefuls are cheap to make but may be in short supply Link: here Clinical Trials Link: here KEVZARA (SARILUMAB) - SANOFI, REGENERON PHARMACEUTICALS Monoclonal antibody approved for inflammatory arthritis, and in trials targeting the “cytokine storm” immune response in severely ill COVID-19 patients. STATUS: Repurposed EARLY RESULTS: 0-3 months Data on arthritis drug to treat coronavirus could come within weeks: Regeneron executive Link: here Exclusive: Sanofi can produce millions of doses of potential coronavirus drug - CEO Link: here Sanofi, Regeneron expand testing of potential coronavirus treatment Link: here Clinical Trials Link: here JAKAVI (RUXOLITINIB) - NOVARTIS, INCYTE Developed to treat inflammatory and autoimmune diseases, and in late-stage development as a cream for atopic dermatitis. One trial each in Canada and Mexico will test the drug in COVID-19 patients with severe respiratory symptoms associated with the “cytokine storm” immune response, with preliminary results expected by June 2020. STATUS: Repurposed EARLY RESULTS: 0-3 months Key China coronavirus hospital says HIV drug beneficial to patients Link: here Mylan waives exclusive U.S. distribution rights for potential COVID-19 therapy Link: here Clinical Trials Link: here New England Journal of Medicine, March 2020 Link: here RHACE2 APN01 - APEIRON BIOLOGICS A recombinant human angiotensin converting enzyme 2 (rhACE2) under Phase-2 clinical development in ALI (Acute Lung Injury) and PAH (Pulmonal arterial hypertension). In early April, a trial in the Netherlands launched to test IFX-1 in patients with severe COVID-19 pneumonia, with preliminary results expected in late October 2020. STATUS: Experimental EARLY RESULTS: 12-18 months Epidemic response group ups coronavirus vaccine funding to $23.7 million Link: here Epidemic response group ups coronavirus vaccine funding to $23.7 million Link: here Clinical Trial Link: here *NON-DRUG THERAPIES* Blood plasma from recovered COVID-19 patients is transfused into patients who are currently ill, in the hope the freshly-made antibodies it contains will help fight the virus.

As said here by Christine Soares